Liver Failure, Liver Transplant
Conditions
Keywords
Hypothermic Machine Perfusion, Liver Transplantation, Ischemia-Reperfusion Injury, Ex Vivo Liver Perfusion, Extended Criteria Donors
Brief summary
The goal of this clinical trial is to evaluate whether hypothermic machine perfusion improves liver graft preservation and post-transplant outcomes compared to conventional static cold storage in adult patients undergoing liver transplantation. This study focuses on liver grafts from deceased donors, including those with extended criteria, which are more susceptible to ischemia-reperfusion injury and early graft dysfunction. The main questions it aims to answer are: Does hypothermic machine perfusion reduce ischemia-reperfusion injury and improve early graft function after liver transplantation? Does this preservation strategy improve clinical outcomes, including graft survival, complication rates, and post-transplant recovery, compared to static cold storage? Researchers will compare hypothermic machine perfusion (ex situ, oxygenated perfusion at low temperature) to standard static cold storage to assess differences in graft preservation quality and post-transplant outcomes. Participants will: Receive a liver graft preserved either by hypothermic machine perfusion or static cold storage, according to a 1:1 randomization protocol Undergo standard liver transplantation procedures Be followed after transplantation with clinical, laboratory, imaging, and biomarker assessments at predefined time points (7 days, 30 days, 6 months, and 1 year) Additional evaluations will include biochemical markers of liver function, inflammatory and immunological mediators, mitochondrial function assessment, and histological analysis to better characterize graft injury and recovery.
Detailed description
This is a prospective, single-center, randomized controlled clinical trial designed to evaluate the impact of hypothermic machine perfusion on liver graft preservation and post-transplant outcomes in adult liver transplantation. Liver transplantation is the standard treatment for end-stage liver disease; however, outcomes are strongly influenced by graft quality. The increasing use of extended criteria donors has introduced additional challenges, as these grafts are more susceptible to ischemia-reperfusion injury, a key determinant of early graft dysfunction and post-transplant complications. Conventional static cold storage, although widely used, does not prevent ongoing anaerobic metabolism and progressive depletion of cellular energy stores, contributing to mitochondrial dysfunction, oxidative stress, and inflammatory activation upon reperfusion. Hypothermic machine perfusion has emerged as an alternative preservation strategy by providing continuous oxygenated perfusion under controlled hypothermic conditions. This approach aims to preserve mitochondrial integrity, reduce metabolic stress, and mitigate ischemia-reperfusion injury, thereby potentially improving graft viability and expanding the utilization of marginal organs. In this study, liver grafts from deceased donors will be allocated to either hypothermic machine perfusion or conventional static cold storage. Following procurement, grafts assigned to the intervention group will undergo ex situ hypothermic perfusion using an oxygenated preservation solution under controlled conditions, while the control group will follow standard institutional preservation protocols. All transplant procedures and perioperative management will be conducted according to institutional standards. Post-transplant follow-up will include clinical and laboratory monitoring to assess graft function and detect complications.
Interventions
Hypothermic machine perfusion of the liver graft is performed prior to transplantation using an ex situ perfusion system under controlled conditions, in which an oxygenated perfusate is circulated through the liver graft vasculature.
Liver graft preservation using conventional static cold storage under hypothermic conditions until transplantation.
Sponsors
Study design
Intervention model description
This is a prospective, single-center, two-arm, parallel-group randomized controlled trial comparing two liver graft preservation strategies in adult liver transplantation. Participants will be allocated in a 1:1 ratio to receive a graft preserved either by hypothermic machine perfusion or by conventional static cold storage. Randomization will be performed using a computer-generated sequence, with each participant assigned to a single intervention arm and no crossover between groups. The intervention is applied at the graft level prior to transplantation. All transplant procedures and perioperative management will be conducted according to standard institutional protocols.
Eligibility
Inclusion criteria
Donor-related inclusion criteria: * Liver donors with confirmed diagnosis of brain death. * Extended criteria donors (ECD). * Age ≥18 years. * Family consent for organ donation obtained. * Negative serology for HTLV, HIV, Chagas disease, and hepatitis B and C. Recipient-related inclusion criteria: * Adult patients (≥18 years) undergoing liver transplantation. * Diagnosis of end-stage liver disease or indication for liver transplantation. * Candidates for primary liver transplantation. * Ability to understand and provide written informed consen Donor-related
Exclusion criteria
* Presence of moderate or severe hepatic steatosis. * Pediatric donors. * Donors classified as ideal, defined by the simultaneous presence of all of the following criteria: Age \<35 years, Body mass index (BMI) \<28 kg/m², No history of cardiopulmonary resuscitation, Norepinephrine requirement \<0.5 µg/kg/min, Liver enzymes (AST or ALT) ≥2 times the upper limit of normal, Intensive care unit stay ≤7 days Recipient-related
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Early Allograft Dysfunction (EAD) | Within 7 days after transplantation | Early allograft dysfunction is defined according to established clinical criteria, including at least one of the following within the first 7 days after transplantation: total bilirubin ≥10 mg/dL on day 7, international normalized ratio (INR) ≥1.6 on day 7, or alanine or aspartate aminotransferase (ALT or AST) levels \>2000 IU/L within the first 7 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Liver Function Tests (AST, ALT, Total Bilirubin) | At 7 days, 30 days, 6 months, and 1 year after transplantation | Serial measurements of liver function parameters, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin, obtained through routine laboratory testing following liver transplantation. Values will be analyzed over time to assess graft function and recovery. |
| Incidence of Acute Kidney Injury (AKI) | Within 7 days and up to 30 days after transplantation | Occurrence of acute kidney injury following liver transplantation, defined based on changes in serum creatinine levels according to established clinical criteria. |
| Incidence of Post-Reperfusion Syndrome (PRS) | During transplantation procedure | Occurrence of post-reperfusion syndrome during liver transplantation, defined as a decrease in mean arterial pressure greater than 30% from baseline within the first minutes after graft reperfusion, with or without the need for increased vasopressor support. |
| Incidence of Post-Transplant Complications | Up to 1 year after transplantation | Occurrence of post-transplant complications, including biliary complications, vascular complications, infections, and acute rejection, assessed according to standard clinical definitions and severity grading systems. |
| Graft Survival | Up to 1 year after transplantation | Survival of the transplanted liver graft without the need for retransplantation |
| Patient Survival | Up to 1 year after transplantation | Survival of the transplant recipient following liver transplantation. |
| Length of Intensive Care Unit Stay | From liver transplantation until intensive care unit discharge, up to 30 days | Duration of stay in the intensive care unit following liver transplantation. |
| Length of Hospital Stay | From liver transplantation until hospital discharge, up to 30 days | Duration of hospital stay following liver transplantation. |
Countries
Brazil
Contacts
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)